This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Easton DF, Lesueur F, Decker B, Michailidou K, Li J, Allen J, et al. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. J Med Genet. 2016;53:298–309.
Weber-Lassalle N, Hauke J, Ramser J, Richters L, Groß E, Blümcke B, et al. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. Breast Cancer Res. 2018;20:7.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yamaguchi, K., Furukawa, Y. Response to the correspondence referring to our article “Development of an MSI-positive colon tumor with aberrant DNA methylation in a PPAP patient” by Pilar Mur, Claire Palles, Ian Tomlinson, Laura Valle. J Hum Genet 65, 515–516 (2020). https://doi.org/10.1038/s10038-020-0752-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s10038-020-0752-8